Trial Search Results

Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD

This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Novartis Pharmaceuticals

Stanford Investigator(s):


  • Drug: TQJ230
  • Drug: Placebo


Phase 3


Key Inclusion Criteria

   - Lp(a) ≥ 70 mg/dL at the screening visit, measured at the Central laboratory

   - Myocardial infarction: ≥ 3 months from screening and randomization to ≤ 10 years prior
   to the screening visit

   - Ischemic stroke: ≥ 3 months from screening and randomization to ≤ 10 years prior to
   the screening visit

   - Clinically significant symptomatic peripheral artery disease

Key Exclusion Criteria

   - Uncontrolled hypertension

   - Heart failure New York Heart Association (NYHA) class IV

   - History of malignancy of any organ system

   - History of hemorrhagic stroke or other major bleeding

   - Platelet count ≤LLN

   - Active liver disease or hepatic dysfunction

   - Significant kidney disease

   - Pregnant or nursing women

Other protocol-defined inclusion/exclusion criteria may apply at the end.

Ages Eligible for Study

18 Years - 80 Years

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305